Silence Therapeutics plc is a leading European RNAi company. RNA interference (RNAi), a Nobel Prize winning technology, is one of the most exciting areas of drug discovery today as it can selectively ”silence” genes linked to the onset of disease, thus leading to the creation of a new class of therapeutic products, RNAi therapeutics.

Silence Therapeutics has developed novel, proprietary short interfering RNA (“siRNA”) molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules as they show increased stability against nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This enables the delivery of siRNA molecules to targeted diseased tissues and cells, whilst increasing their bioavailability and intracellular uptake.

Silence Therapeutics is based in London, UK, and Berlin, Germany, and is listed on AiM (LSE:SLN).

Please click the link below to the London Stock Exchange to receive the actual share price information and/or a free annual report.